Last reviewed · How we verify
transdermal fentanyl matrix, gabapentin
This combination uses fentanyl (an opioid mu-receptor agonist) delivered transdermally and gabapentin (a gabapentinoid that modulates calcium channels) to provide synergistic analgesia for chronic pain.
This combination uses fentanyl (an opioid mu-receptor agonist) delivered transdermally and gabapentin (a gabapentinoid that modulates calcium channels) to provide synergistic analgesia for chronic pain. Used for Chronic pain management (specific indication not clearly defined in available literature).
At a glance
| Generic name | transdermal fentanyl matrix, gabapentin |
|---|---|
| Sponsor | Seoul National University Hospital |
| Drug class | Opioid analgesic + gabapentinoid |
| Target | Mu-opioid receptor (fentanyl); alpha-2-delta calcium channel subunit (gabapentin) |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | FDA-approved |
Mechanism of action
Transdermal fentanyl provides sustained opioid analgesia by activating mu-opioid receptors in the central and peripheral nervous system. Gabapentin reduces neuropathic pain by binding to the alpha-2-delta subunit of voltage-gated calcium channels, decreasing excitatory neurotransmitter release. The combination targets both opioid-responsive and neuropathic pain pathways for enhanced pain control.
Approved indications
- Chronic pain management (specific indication not clearly defined in available literature)
Common side effects
- Dizziness
- Somnolence
- Nausea
- Constipation
- Respiratory depression
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: